QR kód

Potentials and practical challenges of terbium-161 labeled radiopharmaceuticals

Abstract Background Due to promising preclinical studies and clinical case reports, Tb-161 labeled radiopharmaceuticals for targeted radionuclide therapy (TRT) have gained interest. Unlike Lu-177, Tb-161 not only emits β− particles, but also Auger and conversion electrons, which may improve the curr...

Celý popis

Uloženo v:
Hlavní autoři: Carolline M. Ntihabose, Maryana Handula, Amber Piet, Savanne Beekman, Louise van Dalen, Negin Eskandari, Asude Aydogan, Debra Stuurman, Corrina de Ridder, Mark Konijnenberg, Yann Seimbille, Erik de Blois
Médium: Artigo
Jazyk:Inglês
Vydáno: SpringerOpen 2025-10-01
Edice:EJNMMI Radiopharmacy and Chemistry
Témata:
Terbium-161
Lutetium-177
Targeted radionuclide therapy (TRT)
Radiopharmaceuticals
Active pharmaceutical ingredient (API)
On-line přístup:https://doi.org/10.1186/s41181-025-00390-3
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky